Similar articles

• Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.

  Musunuru K, Kathiresan S. Musunuru K, et al. Circ Res. 2016 Feb 19;118(4):579-85. doi: 10.1161/CIRCRESAHA.115.306398. Circ Res. 2016. PMID: 26892959 Free PMC article. Review.
• Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.

  Karalis I, Rensen PC, Jukema JW. Karalis I, et al. Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):360-6. doi: 10.1161/CIRCOUTCOMES.111.000014. Epub 2013 May 14. Circ Cardiovasc Qual Outcomes. 2013. PMID: 23674310 Review. No abstract available.
• Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.

  Laforest L, Souchet T, Moulin P, Ritleng C, Desamericq G, Le Jeunne P, Schwalm MS, Van Ganse E. Laforest L, et al. Arch Cardiovasc Dis. 2009 Jan;102(1):43-50. doi: 10.1016/j.acvd.2008.06.021. Epub 2009 Jan 25. Arch Cardiovasc Dis. 2009. PMID: 19233108
• Should raising high-density lipoprotein cholesterol be a matter of debate?

  Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Athyros VG, et al. J Cardiovasc Med (Hagerstown). 2012 Apr;13(4):254-9. doi: 10.2459/JCM.0b013e3283522422. J Cardiovasc Med (Hagerstown). 2012. PMID: 22367577 Review.
• CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.

  Nicholls SJ. Nicholls SJ. Clin Pharmacol Ther. 2018 Aug;104(2):297-300. doi: 10.1002/cpt.1118. Epub 2018 Jun 27. Clin Pharmacol Ther. 2018. PMID: 29901215 Review.